利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

221 条记录 (耗时 0.036 秒)

    COMPOSITIONS AND METHODS VECTORS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORS
    63.
    发明公开
    COMPOSITIONS AND METHODS VECTORS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORS 审中-公开
    合剂和方法，向量给有痘病毒载体改进的免疫反应

    公开(公告)号：EP3074517A1

    公开(公告)日：2016-10-05

    申请号：EP14806215.1

    申请日：2014-11-25

    申请人： Bavarian Nordic A/S

    发明人： HAUSMANN, Jürgen ,  WOLFERSTÄTTER, Michael

    IPC分类号： C12N15/86

    CPC分类号： C12N15/117 ,  A61K39/39 ,  A61K2039/55561 ,  C12N7/00 ,  C12N15/86 ,  C12N2310/17 ,  C12N2310/53 ,  C12N2330/51 ,  C12N2710/24021 ,  C12N2710/24043 ,  C12N2710/24063

    摘要： Provided herein are recombinant poxviruses comprising heterologous or native nucleic acids specifying excess double-stranded RNA (dsRNA) early in infection, which may further comprise heterologous nucleic acids encoding one or more costimulatory molecules, and/or heterologous nucleic acids encoding one or more infectious disease-associated antigens or tumor-associated antigens, as well as pharmaceutical compositions comprising such recombinant poxviruses and methods and uses thereof. The recombinant poxviruses provided herein enhance innate and adaptive immune activation in subjects compared to identical recombinant poxviruses lacking heterologous or native transcription units specifying excess early dsRNA.

    摘要翻译： 提供在是包含异源或天然核酸指定过量的双链RNA（dsRNA的）在感染早期，其还可包含异源核酸编码一种或多种共刺激分子，和/或异源核酸编码一种或多种感染性疾病的重组痘病毒 - 相关抗原或肿瘤相关抗原，以及药物组合物，包含重组寻求痘病毒和方法及其用途。 在所提供的重组痘病毒增强先天和在受试者适应性免疫激活与缺少异源或天然的转录单位指定过量早期的dsRNA相同重组痘病毒。

    RECOMBINANT VECTOR WITH OPTIMIZED A-BULGE
    65.
    发明公开
    RECOMBINANT VECTOR WITH OPTIMIZED A-BULGE 审中-公开
    具有改进的A-VAULT重组载体

    公开(公告)号：EP3030659A1

    公开(公告)日：2016-06-15

    申请号：EP14835030.9

    申请日：2014-08-05

    申请人： Tocagen Inc.

    发明人： LIN, Amy H. ,  GRUBER, Harry E. ,  IBANEZ, Carlos ,  JOLLY, Douglas J.

    IPC分类号： C12N15/113

    CPC分类号： C12N15/111 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/32 ,  C12N2330/51

    摘要： The disclosure describes replication competent retroviral vectors (RCR) for gene therapy and gene delivery. The RCR includes an IRES sequence having 6-7 A's in A-bulge of the bifurcation region. The disclosure provides recombinant replication competent retrovirus comprising: a retroviral GAG protein; a retroviral POL protein; a retroviral envelope; a retroviral polynucleotide comprising Long-Terminal Repeat (LTR) sequences at the 3' end of the retroviral polynucleotide sequence, a promoter sequence at the 5' end of the retroviral polynucleotide.